Guest: Putao Cen, MD Tune in to hear Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School, discussing the clinical presentations of tumor sidedness in colorectal cancer patients and how it affects diagnosis, prognosis, and treatment.

Conversations on Colorectal Cancer

Characteristic Clinical Presentations of Tumor Sidedness: Diagnostic & Prognostic Impacts

Guest: Putao Cen, MD Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

Guest: Putao Cen, MD When a patient with metastatic colorectal cancer experiences adverse events like complete obstruction and tumor perforations, it can further complicate an already-difficult disease to manage. That’s why Dr. Putao Cen is here to reveal his key strategies in managing these and other adverse events in metastatic colorectal cancer.

An Oncologist’s Keys to Managing Adverse Events in mCRC Care

Host: John J. Russell, MD Guest: Axel Grothey, MD Since biomarker testing can aid in the creation of individualized treatment plans, Dr. Axel Grothey is here to provide his perspective on the current state of biomarker testing for colorectal cancer and how we can increase biomarker testing practices at the time of diagnosis.

Addressing Gaps in Biomarker Testing for mCRC at Diagnosis

Host: John J. Russell, MD Guest: Axel Grothey, MD In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.

Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

Host: John J. Russell, MD Guest: Axel Grothey, MD Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

Guest: Benjamin A. Weinberg, MD Dr. Benjamin Weinberg, assistant professor at Georgetown University, examines the determinants of disease progression of metastatic colorectal cancer and how these can lead to better approaches to tailored care and personalized management of your patients. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only. 

Unraveling Disease Progression Predictors of mCRC

Guest: Benjamin A. Weinberg, MD Over the years, tumor sidedness has become an area of immense interest for the oncology community. And while they have shown inferior outcomes for patients with the primary site on the right side versus the left, questions still remain as to why. Dr. Benjamin Weinberg, an Assistant Professor at Georgetown University, details why sidedness may be a prominent prognostic indicator. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Right-Left Divide: Prognostic Importance of Tumor Sidedness

Guest: Benjamin A. Weinberg, MD The NCCN guidelines are the foundation of clinical practice, supporting the decisions of all in the oncology community. For this reason, advancements in the therapeutic landscape of metastatic colorectal cancer have led to necessary adaptations of the guidelines. Reflecting on these influential modifications is Dr. Benjamin Weinberg, Assistant Professor at Georgetown University. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Expanding NCCN Guidelines for mCRC Care

Guest: Benjamin A. Weinberg, MD Keeping up with rapid advancements in mCRC, the NCCN updated their guidelines to encompass the perplexity of tumor sidedness. Dr. Benjamin Weinberg, Assistant Professor at Georgetown University, interprets the distinctions between right versus left-sided tumor sites and how these developments could impact your treatment selection for patients. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

NCCN Guidelines on mCRC in an Era of Tumor Sidedness

Host: Shira Johnson, MD Guest: Edmond Bendaly, MD, FACP From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everything down with Dr. Shira Johnson is Dr. Edmond Bendaly, chairman and liaison of the Cancer Committee at Marion General Hospital in Marion, Indiana. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

The Role of Targeted Therapy in Metastatic Colorectal Cancer Patient Care

Guest: Richard Kim, MD Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

How mCRC Tumor Sidedness Guides Treatment Decisions

Guest: Richard Kim, MD Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Cancer Center. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

What Is the Role of KRAS Testing in Therapeutic Decision Making for mCRC?

Guest: Richard Kim, MD There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

mCRC Case Review: How to Make Informed Decisions for Personalized Treatment

Guest: Edmond Bendaly, MD, FACP Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

The Standouts: One Colorectal Cancer Patient’s Story

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location. To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC). This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.    Sponsored by

hubhopper

Conversations on Colorectal Cancer

hubhopper